MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2024 International Congress

September 27-October 1, 2024. Philadelphia, PA.

View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z
  • Naturalistic walking in Parkinson’s disease: Prefrontal cortex activity measured with functional near-infrared spectroscopy (fNIRS)

    R. Kaplan, N. Mukadam, C. Aul, M. Rowe, N. Eklund, T. Nordahl, M. Yücel, T. Ellis, A. Cronin-Golomb (Boston, USA)

  • Neural Correlates of Dual Task Touchscreen Performance in Parkinson’s Disease

    J. de Vleeschhauwer, N. D'Cruz, I. Orlando, J. Tan, E. Nackaerts, W. Vandenberghe, S. Lewis, M. Shine, A. Nieuwboer (Leuven, Belgium)

  • Neural oscillatory dynamics in Parkinson disease and dystonia: Insights from EEG analysis

    M. Alam, A. Beck, K. Schwabe, J. Krauss (Hannover, Germany)

  • Neural Signatures of Laryngeal Dystonia during Asymptomatic Tasks of Sequential and Learned Finger-Tapping

    M. Day, G. Battistella, K. Simonyan (Boston, USA)

  • Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.

    C A. Hurtado-Gonzalez, J F. Ayala-Rico, S. Ospina-Otalvaro, P A. Lenis, J M. Márquez, C O. Moreno, M. Agudelo, S. Guerrero (Cali, Colombia)

  • Neurodegeneration with brain iron accumulation in pediatric population: Clinico-radiologic and genetic features

    D. Kalikavil Puthanveedu, A. Cherian (Thiruvananthapuram, India)

  • Neuroimaging Factors Differentially Associated with Pathology and Clinical Presentation

    J. Pommy, S. Bouchachi, A. Bryant, V. Thornton, C. Nguyen, J. Truelove, K. Rawson, J. Icehour, M. Knopp, C. Wright, D. Scharre (Columbus, USA)

  • Neuronal Exosome based markers in Parkinson’s Disease and Progressive Supranuclear Palsy

    A. Roy, S. Brahmachari, A. Pantelyat, L. Rosenthal, V. Dawson, T. Dawson (Baltimore, USA)

  • Neuropathological Synergy in Cauda Equina Syndrome, Parkinson’s Disease, And Depression: Breaking the Dysphoric Cycle

    R. Grace, L. Velez, R. Islam, B. Carr (Gainesville, USA)

  • Neuropeptide Alterations in Parkinson’s Disease: A Meta-Analysis

    MA. Muneer, V. Suresh, S. Aujla, A. Khare, P. Gowda, V. Ghosh, T. Dave (Lahore, Pakistan)

  • Neurophenomenological Aspects of Monocular Visual Hallucinations in Charles Bonnet Syndrome in a patient with Parkinson’s Disease

    D. Nolasco, A. Makarem, B. Buchowicz, L. Schmidt, B. Carr (Gainesville, USA)

  • Neurophysiological Underpinnings of Apathy in Parkinson’s Disease Versus Depressive Disorders: A Comparative Study

    D. Nolasco, A. Sohel, B. Carr (Gainesville, USA)

  • Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

  • Neuroprotective Action of Exogenous Melatonin in Parkinson Disease Patients and its Impact on Daily Routine: a Systematic Review

    G. Maia, P. Silva, M. Rosa, R. Albuquerque, E. Almeida, C. Menegon, V. Serafim, F. Oliveira, G. Sorato, I. Fink, C. Rieder (Porto Alegre, Brazil)

  • Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish

    KHA. Aran (Moga, India)

  • Neuroprotective Efficacy of Ethanolic Extract from Amorphophallus Paeoniifolius Tuber Against Haloperidol-Induced Parkinson’s Disease Model

    R. Kumar, S. Choudhary (Handia,, India)

  • Neuroprotective role of baicalein via autophagy mediated modulation of associated motor proteins in experimental animals of Parkinson disease

    D. Khatri, P. Naren (Hyderabad, India)

  • Neuropsychiatric Manifestations in Patients with Degenerative Cerebellar Ataxias from Serbia

    A. Milovanovic, O. Tamaš, G. Marić, M. Janković, M. Kostić, B. Salak đokić, E. Stefanova, N. Dragašević Mišković (Belgrade, Serbia)

  • Neuropsychiatric symptoms in patients with probable Progressive supranuclear palsy in reference centers of Valle del Cauca- Colombia

    V. Martínez-Villota, L. Ortega-Bolaños, C. Hurtado-Gonzalez (Pasto, Colombia)

  • Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease

    J. Zitser, S. Forner, K. Wong, J. Chengshi, J. Neuhaus, M. Kim, M. Hakimi, I. Allen, B. Miller, H. Rosen, K. Rankin, M. Geschwind (Tel Aviv, Israel)

  • Neuropsychological Predictors of Cognitive Decline in Parkinson’s Disease: A Systematic Review (PDCogniCare)

    D. Pourzinal, K. Sivakumaran, J. Yang, D. Bailey, L. Mitchell, D. Brooks, A. Lehn, J. Liddle, N. Pachana, H. Tinson, K. Shrubsole, N. Dissanayaka (Herston, Australia)

  • Neuropsychological Tests of Language, Memory, and Visuospatial Function in Parkinson’s Disease: Review, Critique and Recommendations

    O. Bezdicek, R. Biundo, D. Cammisuli, B. Cholerton, J. Dalrymple-Alford, N. Edelstyn, E. Fiorenzato, E. Holker, S. Martinez-Horta, A. Martini, G. Santangelo, B. Segura, C. Siri, A. Troster, M. Skorvanek, D. Weintraub, G. Geurtsen (Praha, Czech Republic)

  • Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein

    N. Tayebi, B. Berhe, B. Aleksandra, J. Lichtenberg, A. D'Souza, M. Henderson, T. Chen, A. Alvarez, S. Zanlungo, M. Cookson, J. Marugan, E. Sidransky (Bethesda, USA)

  • Neurovascular Involvement in Parkinson’s Disease Cognitive Impairment: A 4D Flow Study

    A. Deane, D. Myall, A. Pilbrow, R. Shoorangiz, A. Sharifzadeh-Kermani, T. Anderson, J. Dalrymple-Alford, C. Morgan, T. Melzer (Christchurch, New Zealand)

  • New onset movement disorders following COVID-19 infection

    D. van Wamelen, B. Facer, S. Rota, M. Bonello, K. Chaudhuri, G. Breen, B. Michael (London, United Kingdom)

  • New Pathological Findings in an International Cohort of Hereditary Spastic Paraplegia 4 Patients

    A. Orlacchio, A. Meyyazhagan, P. Eusebi, P. Basavaraju, H. Kuchi Bhotla, M. Stasi, G. Ribas, I. Faber, R. Miyamoto, M. Miele, R. Massa, P. Patti, M. França Jr, J. Pedroso, O. Barsottini, H. Teive, T. Kawarai, E. Panza (Perugia, Italy)

  • New α-Synuclein Strain Biomarker in Parkinson’s Disease and Related Dementia

    K. Gadhave, R. Chen, V. Dawson, T. Dawson, L. Rosenthal, X. Mao ()

  • NGS diagnosis rate in a combined cerebellar ataxia and spastic paraplegia series from southern Spain

    A. Adarmes Gómez, S. Jesús Maestre, D. Macias Garcia, F. Carrillo Garcia, L. Muñoz Delgado, P. Gómez Garre, P. Mir (Sevilla, Spain)

  • Nigral Neuroinflammation and Dopaminergic Neurons in PD, MSA and PSP: A Comparative Clinicopathological Study

    E. Backman, M. Gardberg, L. Luntamo, M. Peurla, T. Vahlberg, P. Borghammer, N. Stefanova, G. Wenning, V. Kaasinen (Turku, Finland)

  • No Association between Anemia and Risk of Parkinson’s Disease: Evidence From A Meta-Analysis Using Real-World Evidence

    S. Zayed, S. Tabassum (Ranchi, India)

  • Nocturnal Blood Pressure, Non-Dipping, Psychosis And Non-Motor Symptoms In Early Stages Of Huntington’s Disease Patients

    R. Singh, V. Sharma (New Delhi, India)

  • Nocturnal Bradykinesia is better detected using wearable sensors in Parkinson’s disease compared to clinical outcome

    I. Murasan, M. Qamar, K. Poplawska-Domaszewicz, D. Trivedi, K R. Chaudhuri, C. Falup-Pecurariu (Brasov, Romania)

  • Nocturnal Hypertension in Parkinson’s Disease. The Flip Side of a Tainted Coin

    D. Wilson, M. Hagens, S. Nagaratnam, V. Fung (Sydney, Australia)

  • Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study

    T. Gurevich, S. O'Sullivan, J. Parra, M. O'Meara, J. Zamudio, A. Fasano (Tel Aviv-Yafo, Israel)

  • Non Classified Spinocerebellar Ataxia-like Syndrome due to GYG-1 gene mutation with TPM3, GEMIN5 and DES mutations in a Peruvian family

    W. Trillo Alvarez, A. Escalante Mercado, D. Hito Cano, L. Delgado Villanueva, K. Choque Pereyra, E. Carrillo Monteagudo, P. Gonzales Romero (Arequipa, Peru)

  • Non motor symptoms assessment in Primary Familial Brain Calcification, survey on a cohort

    G. Bonato, M. Carecchio (Padova, Italy)

  • Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

  • Non-invasive transcranial Eectrical Stimulation (tRNS and tACS) targeting the Pallidum in normal Controls and PD Patients by rotating electrical Fields

    Z. Soltaninejad, A. Szelenyi, A. Hunold, U. Fietzek, K. Ma, S. Goetz, A. Antal, A. Straube, W. Paulus (Munich, Germany)

  • Non-Motor Symptoms and Comorbidities in a Cohort of Puerto Rican Parkinson’s Disease: Do They Affect Severity and Progression?

    C. Serrano, K. Palermo, M. Morales, V. Wojna (San Juan, Puerto Rico)

  • Non-motor Symptoms and Quality-of-life of People with Parkinson’s disease

    K. Prakash, X. Xiao, EC. Lim (Singapore, Singapore)

  • Non-motor symptoms in people with Huntington’s disease: use and validation of the MDS Non-Motor Scale (MDS-NMS)

    JM. Valera-Bermejo, N. Martins, O. Makos, J. Badenoch, M. Hartmann, A. Rangel-Cristales, A. Rizos, K. Ray Chaudhuri, D. van Wamelen (London, United Kingdom)

  • Nonmotor symptoms in Spinocerebellar ataxia type 12 (SCA 12)

    S. Choudhury, P. Basu, S. Mondal, R. Banerjee, J. Ganguly, M. Tiwari, H. Kumar (Kolkata, India)

  • Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.

    R. Durcan, J. Rowe (Cambridge, United Kingdom)

  • Normal pressure hydrocephalus in two Parkinson’s disease patients with deep brain stimulation – co-occurrence or complication

    B. Borgohain, S. Kola, M. Karri, R. Alugolu, R. Kandadani (Hyderabad, India)

  • NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease

    M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Wuhan, China)

  • Novel ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety

    S. Smieszek, B. Przychodzen, C. Tyner, C. Johnson, C. Polymeropoulos, G. Birznieks, M. Polymeropoulos (Washington, USA)

  • Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease

    Z. Afshari, N. Nguyen, M. Afshari (Glenview, USA)

  • Novel Partial Gene Deletion in CaCNA1A Presenting with Gait Ataxia, Vertigo, and Abnormal Eye Movements

    D. Mohanty, I. Bledsoe (San Francisco, USA)

  • Nutritional Status Implication at 6 Months in Parkinson’s Disease: Follow-Up Results

    N. Ayo Mentxakatorre, B. Tijero, T. Fernandez-Valle, A. Ortiz-de-Echevarria, M. Acera Gil, I. Chavarri Rubio, C. Juanes Moreno, M. Ruiz-Lopez, JC. Gomez-Esteban, R. Del Pino (Barakaldo, Spain)

Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley